A Prospective Study on the Prevalence of <scp>MASLD</scp> in Patients With Type 2 Diabetes and Hyperferritinaemia
Maral Amangurbanova(University of California San Diego), Rohit Loomba(University of California San Diego), Nabil Noureddin(University of California San Diego), Scarlett Lopez(University of California San Diego), Harris Siddiqi(University of California San Diego), Kaleb Tesfai(University of California San Diego), Richelle Bettencourt(University of California San Diego), Egbert Madamba(University of California San Diego), Vanessa Cervantes(University of California San Diego), Daniel Q. Huang(National University of Singapore)
Cited by 22
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k